1696 POSTER A subcutaneous injection device for delivery of Aranesp? (darbepoetin alfa), an erythropoiesis-stimulating protein (ESP), in anaemic patients with cancer receiving chemotherapy

首页> 外文期刊>European Journal of Cancer Supplements >1696 POSTER A subcutaneous injection device for delivery of Aranesp? (darbepoetin alfa), an erythropoiesis-stimulating protein (ESP), in anaemic patients with cancer receiving chemotherapy

【24h】

1696 POSTER A subcutaneous injection device for delivery of Aranesp? (darbepoetin alfa), an erythropoiesis-stimulating protein (ESP), in anaemic patients with cancer receiving chemotherapy

机译：1696 POSTER用于递送Aranesp？的皮下注射装置？（darbepoetin alfa），一种促红细胞生成蛋白（ESP），用于接受化疗的贫血癌症患者

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 microg every 3 weeks in anaemic cancer patients receiving chemotherapy. [J] . Eisterer W, Hussl C, Erb H, Current medical research and opinion . 2011,第2期

机译：回顾：在接受化疗的贫血癌症患者中，每3周评估一次darbepoetin alfa 500微克的输血率。
2. 1155 POSTER A prospective observation study of treatment of chemotherapy-induced anaemia with darbepoetin alfa every 3 weeks: the OASIS (Observational Aranesp? Survey to Investigate the q3w Schedule) study [J] . D.Verhulst, K.Pat, B.Anrys, European Journal of Cancer Supplements . 2007,第4期

机译：1155海报每3周一次用达比泊汀阿尔法治疗化疗引起的贫血的前瞻性观察研究：OASIS（观察性Aranesp？调查以调查q3w时间表）研究
3. 1283 POSTER Darbepoetin alfa administered once every 3 weeks (Q3W) is effective for treating anaemia in patients receiving multicycle chemotherapy: results of a randomised, double-blind, active-controlled trial [J] . European Journal of Cancer Supplements . 2005,第2期

机译：每3周（Q3W）施用1283次POSTER Darbepoetin alfa可有效治疗接受多周期化疗的患者的贫血：一项随机，双盲，主动对照试验的结果
4. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents darbepoetiN alfa (BRIGHTEN Trial) [O] . Hideki Kato, Masaomi Nangaku, Hideki Hirakata, -1

机译：慢性肾病合并肾脏贫血的患者的观察性临床研究的依据和设计：对促红细胞生成促进剂低反应性贫血的阿尔法患者darpropoetiN alfa的肾脏预后（BRIGHTEN试验）
5. PCN108 PSYCHOMETRIC VALIDATION OF A PATIENT QUESTIONNAIRE EVALUATING SATISFACTION WITH A DARBEPOETIN ALPHA PRE-FILLED DEVICE FOR SELF-INJECTION (ARANESP®SURECLICKTMDEVICE), AND A HOME-SERVICE (2CARE®SERVICE) IN CHEMOTHERAPY-INDUCED ANAEMIC CANCER PATIENTS [O] . de Jong FA, Viala-Danten M, van Herwaarden RH, 2010

机译：PCN108对使用达贝替丁α预制设备进行自我注射（ARANESP®SURECLICKTMDEVICE）和家庭用药（2CARE®SERVICE）的化疗引起的患者满意程度评估的患者问卷调查的验证

1696 POSTER A subcutaneous injection device for delivery of Aranesp? (darbepoetin alfa), an erythropoiesis-stimulating protein (ESP), in anaemic patients with cancer receiving chemotherapy

著录项

相似文献

相关主题

期刊订阅